WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016085990) COMPOSITIONS AND METHODS RELATING TO INHIBITING SERINE HYRDOXYMETHYLTRANSFERASE 2 ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/085990    International Application No.:    PCT/US2015/062442
Publication Date: 02.06.2016 International Filing Date: 24.11.2015
IPC:
A61K 31/44 (2006.01), A61K 31/505 (2006.01), A61P 35/00 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; 1600 Huron Parkway, 2nd Floor Ann Arbor, Michigan 48109-2590 (US)
Inventors: NEAMATI, Nouri; (US).
XU, Shili; (US).
TAMURA, Shuzo; (US)
Agent: GOETZ, Robert A.; (US)
Priority Data:
62/083,564 24.11.2014 US
Title (EN) COMPOSITIONS AND METHODS RELATING TO INHIBITING SERINE HYRDOXYMETHYLTRANSFERASE 2 ACTIVITY
(FR) COMPOSITIONS ET PROCÉDÉS RELATIFS À L'INHIBITION DE L’ACTIVITÉ SÉRINE HYDROXYMÉTHYLTRANSFÉRASE 2
Abstract: front page image
(EN)The present invention relates to small molecule compounds capable of inhibiting serine hydroxylmethyltransferase 2 (SHMT2) activity, methods for the discovery of such compounds, and related research and therapeutic uses for such compounds. In particular, the present invention provides compounds capable of inhibiting SHMT2 activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with diseases and other pathophysiological states caused by or associated with aberrant SHMT2 activity (e.g., cancer).
(FR)La présente invention concerne des composés à petite molécule capables d'inhiber l’activité sérine hydroxyméthyltransférase 2 (SHMT2), des procédés pour la découverte de ces composés et des utilisations en recherche et thérapeutiques de ces composés. En particulier, la présente invention concerne des composés capables d'inhiber l'activité SHMT2, et des procédés d'utilisation de ces composés en tant qu’agents thérapeutiques pour traiter un certain nombre d’affections associées à des maladies et d’autres états physiopathologiques causés par ou associés à une activité SHMT2 aberrante (par exemple, un cancer).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)